Standard

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. / Dekempeneer, Yana; Back, Tom; Aneheim, Emma; Jensen, Holger; Puttemans, Janik; Xavier, Catarina; Keyaerts, Marleen; Palm, Stig; Albertsson, Per; Lahoutte, Tony; Caveliers, Vicky; Lindegren, Sture; D'Huyvetter, Matthias.

In: Molecular Pharmaceutics, Vol. 16, No. 8, 08.2019, p. 3524-3533.

Research output: Contribution to journalArticleResearchpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{50060fe3adc34f338d3c31db594dcb74,
title = "Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior",
keywords = "nanobody, targeted alpha therapy, breast cancer, astatine-211, HER2",
author = "Yana Dekempeneer and Tom Back and Emma Aneheim and Holger Jensen and Janik Puttemans and Catarina Xavier and Marleen Keyaerts and Stig Palm and Per Albertsson and Tony Lahoutte and Vicky Caveliers and Sture Lindegren and Matthias D'Huyvetter",
year = "2019",
month = "8",
doi = "10.1021/acs.molpharmaceut.9b00354",
language = "English",
volume = "16",
pages = "3524--3533",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "8",

}

RIS

TY - JOUR

T1 - Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior

AU - Dekempeneer, Yana

AU - Back, Tom

AU - Aneheim, Emma

AU - Jensen, Holger

AU - Puttemans, Janik

AU - Xavier, Catarina

AU - Keyaerts, Marleen

AU - Palm, Stig

AU - Albertsson, Per

AU - Lahoutte, Tony

AU - Caveliers, Vicky

AU - Lindegren, Sture

AU - D'Huyvetter, Matthias

PY - 2019/8

Y1 - 2019/8

KW - nanobody

KW - targeted alpha therapy

KW - breast cancer

KW - astatine-211

KW - HER2

U2 - 10.1021/acs.molpharmaceut.9b00354

DO - 10.1021/acs.molpharmaceut.9b00354

M3 - Article

VL - 16

SP - 3524

EP - 3533

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 8

ER -

ID: 46962729